Immunogenomic Landscape of Hematological Malignancies

Abstract

We report the immunogenomic landscape of >10,000 hematological malignancies by integrating large-scale genomic, epigenomic, and transcriptomic datasets in this article. During its preparation, we submitted an incorrect version of Figure 1A, in which the numbers of the cases in the Hemap dataset were incorrect (1,288 and 4,293 lymphoma and leukemia samples, respectively; the correct numbers are 1,300 and 4,281). Similarly, in Figure S1A, the number of cell lines in CCLE dataset was incorrect (CHL n = 9 changed to n = 8, and unknown n = 7 is now included). The number of cases reported in the first paragraph of the Results section has also been corrected to reflect these revisions (''We used 7,092 samples from 36 hematological malignancies, with 770 healthy donor hematological cell populations and 610 cell lines as controls [Pö lö nen et al., 2019], to comprehensively analyze immunological properties in hematological cancer transcriptomes [Figures 1A and S1A; Table S1]''). These errors do not affect any of the data or conclusions in the article, and the figures have been revised in the online and printed versions of the paper, which differ from the version originally published online on July 9, 2020. We apologize for any confusion these errors may have caused.

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia

“…Of note, a close association between the immunological TME and cancer-intrinsic genomic alterations has been recently highlighted 42 and correlated to the response to chemotherapy. In AML, a specific TME-related immunogenomic profile correlates with increased chemoresistance and with response to immunotherapy 43 and a correlation between TP53 mutations and an immunosuppressive TME has been recently established 44,45 .…”

Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas

“…Tumors without such genetic evasion strategies are likely immunogenic and must escape from T cell pressure in other ways-their frequent development in extranodal (and immune-privileged) sites is well established (Bruno et al, 2014;Kraan et al, 2013;Shi et al, 2019). These findings also help explain the weak clinical outcomes in single-agent checkpoint blockade trials (Ansell et al, 2019;Lesokhin et al, 2016), even though ABC tumors display inflamed phenotypes and can express checkpoint inhibitors (Dufva et al, 2020). Ultimately, NK-mediated or CAR-T therapies could be better suited for ABC DLBCL.…”

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia

“…This includes variability in the presence of cytotoxic lymphocytes, HLA II expression, activating and inhibitory signals produced by tumor cells and antigen presenting cells (APCs), as well as cancer neoantigens. In a broad analysis of patients with hematological malignancies, those with acute leukemias had the lowest cytolytic scores, reflecting lower T and NK cell fractions in the bone marrow ( 18 ). Certain AML subgroups appear to have distinct immunological phenotypes.…”